Wet Macular Degeneration Study to Compare Ranibizumab or Bevacizumab to Aflibercept

Part of paid clinical trials in Cleveland, Ohio.

Sponsor
Rishi Singh
Study ID
NCT01617148
Phase
PHASE4
Status
Completed

Conditions

  • Exudative Macular Degeneration

Eligibility Criteria

Sex
ALL
Age
50 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Aflibercept — DRUG
    Patients received 2 mg (0.05 mL) of intravitreal aflibercept injection administered monthly for the first 3 months, followed by 2 mg (0.05 mL) once every 2 months as per the drug label for the next 9 months.

Study Details

This study will examine the use of Aflibercept in patients with exudative macular degeneration requiring intravitreal injections. Patients will be followed for 24 months. The follow up phase will be completed at month 36.

Key Dates

Start date
Jun 30, 2012
Status verified
Jul 2018
Primary completion
Dec 31, 2013
Completion
Dec 31, 2015

Study Design

Enrollment
26 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment with Aflibercept
    Subjects were given 2 mg (0.05 mL) of intravitreal aflibercept injection administered every month for the first 3 months, followed by 2 mg (0.05 mL) once every 2 months as per the drug label for the next 9 months.

Primary Outcome Measure

Change in Central Subfield Thickness From Baseline at 12 Months [ Time Frame: baseline and 12 months ]

Locations (1)

FacilityCityStateZIPSite coordinators
Cole Eye Institute, Cleveland ClinicClevelandOhio44195-

Find similar trials in Cleveland, OH

By research site
Cole Eye Institute, Cleveland Clinic· Cleveland, OH

Related Studies